Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog
Joyce de Langen

Joyce de Langen

Senior Solution Manager Pharmacovigilance

Connect with Joyce de Langen on LinkedIn
Follow Joyce de Langen on Twitter

About the author: I am a pharmacist by training. I joined Elsevier last month as Senior Solution Manager Pharmacovigilance. I am working in the pharmacovigilance and drug safety domain for more than 10 years. I started my professional career at the Netherlands Pharmacovigilance Centre for spontaneous adverse event reporting. After 6 years I teached pharmacotherapy and pharmacoepidemiology at the University of Utrecht and the last 5 years of my professional live I worked in the pharmaceutical industry (Abbott/AbbVie and Sanquin Plasma Products) in different roles within pharmacovigilance. Prior to working to Elsevier I was the qualified person for pharmacovigilance with Sanquin Plasma Products.

Posts by Joyce de Langen

Monitoring literature for Benefit-Risk Evaluation: a Life-Time Responsibility

Posted on January 15th, 2016 in Pharmacovigilance

Monitoring worldwide experience

The purpose of drugs is to cure or alleviate symptoms of disease. However, drugs do not only have therapeutic effects, they may also cause adverse drug reactions (ADRs). (more…)

Social Media Screening for ADR-monitoring – Like it or not!

Posted on December 16th, 2015 in Pharmacovigilance

Social Media and Pharmacovigilance

Limitations of clinical trials and traditional post-marketing sources of safety information. 

Due to limitations of pre-marketing clinical trials, there isn’t much information available once a medicinal product is authorized for marketing. (more…)

French ePharmaDay 2015: New EU Clinical Trial Regulation and Data Transparency

Posted on November 24th, 2015 in Pharmacovigilance

On 16 April 2014, the new EU Clinical Trial Regulation on medicines for human use was adopted. The purpose of the new Clinical Trial Regulation is to create an environment that is favourable for conducting clinical trials, with the highest standards for patient safety, within the EU. (more…)

Screening Scientific Literature for Adverse Drug Reactions: Relevant for Patient Safety or Just a Time-Consuming Regulatory Obligation?

Posted on November 16th, 2015 in Pharmacovigilance

An adverse drug reaction (ADR) is defined as any response to a medicinal product which is noxious and unintended. ADRs are a major public health problem, accounting for up to 5% of all hospital admissions and 28% of the emergency visits. Of all hospitalized patients, 5% experience an ADR during the hospitalization (more…)

  1. 1
  2. 2